趋化因子与乳腺癌

The relationship between chemokines and breast cancer

趋化因子参与乳腺癌细胞的生长、血管生成及远处转移过程。然而,近年来单靶点趋化因子受体拮抗剂的临床试验多以失败告终,彰显了肿瘤微环境中趋化因子网络的复杂性,因此基于多向药理学原理确立多靶点调控策略势在必行。多靶点非典型性趋化因子受体(ACR)作为内源性和生理性的调节分子,有可能成为捕获高表达的多种促肿瘤性趋化因子、有效控制乳腺癌的利器。

Many chemokines and chemokine receptors, such as CCL2 and CXCR4, participate in the growth, angiogenesis, distal metastasis of breast cancer. However, the recent failures in the clinical trials of some single target antagonists suggest that chemokine network in tumor microenvironment is really complicated. Obviously, multi- targets regulation strategy for chemokines is indispensable based on the polypharmacological principle in the future. Atypical chemokine receptors （ACR） as endogenous and physiological regulators, including Duffy antigen receptor for chemokines （DARC）, D6 and ChemoCentryx chemokine receptor （CCX-CKR）, may be the powerful candidates for this purpose.